PANITUMUMAB

Neoplasm

Astellas Pharma Incmonoclonal_antibodyPhase 2Active

BBB

73/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 95/ 100

Competitive context

889 Active assets in the Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Granulocyte Colony-Stimulating Factor Lenograstim Sanofi	Phase 4	BB
Dexmedetomidine Medical College of Wisconsin	Phase 4	BB
Lidocaine Medical College of Wisconsin	Phase 4	BB
Relatlimab Bristol-Myers Squibb	Phase 2	BB
VITAMIN D Tanta University	Phase 4	BB

View all 50 →

Same molecule, other indications

PANITUMUMAB is also rated in:

colorectal cancerActive

BB

Indicative · Phase 3

68 / 100

rectal carcinomaDormant

BB

Indicative · Phase 2

67 / 100

colon adenocarcinomaActive

BB

Indicative · Phase 3

66 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.